Arca
Skip to content
Tools
Tools

Embryonal rhabdomyosarcoma

Drug research and approvals for embryonal rhabdomyosarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 23 studies of embryonal rhabdomyosarcoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.

  • Recruiting worldwide: 23
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 23 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 6

Phase 2 4

How its trials ended

37 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 7 whose ending is known, 29% met their primary endpoint, 43% missed it and 29% stopped early.

  • Completed, result not reported2362%
  • Ongoing719%
  • Missed its primary endpoint38%
  • Met its primary endpoint25%
  • Stopped: sponsor or business decision13%
  • Stopped: other or unclear13%

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.